Global HIV Diagnostics Testing Market - 2021-2028

Global HIV Diagnostics Testing Market - 2021-2028

Market Overview

The global HIV diagnostics testing market size was valued at US$ XX million in 2020 and is estimated to reach US$ XX million by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

HIV diagnostics are used to detect the human immunodeficiency virus in saliva, serum, or urine. HIV diagnostics aids in detecting antibodies, RNA, and antigens.

Market Dynamics

The factors influencing the global HIV diagnostics market are the increasing demand for HIV diagnostics, and the growing prevalence of HIV is expected to drive the market growth.

The increasing demand for HIV diagnostics is expected to drive market growth in the forecast period

The increasing awareness about HIV is expected to drive the demand for HIV diagnostics testing. For instance, India's AIDS Control Program is widely regarded as a success story worldwide. The National AIDS Control Programme (NACP) is being implemented as a comprehensive programme for HIV/AIDS prevention and control in India. Over time, the emphasis has shifted from raising awareness to behaviour change, from a national response to a more decentralized response, and increased involvement of NGOs and PLHIV networks to increased involvement of PLHIV networks.

Coordinated action is urgently needed in low- and middle-income countries (LMICs) with the highest HIV burden to ensure that the ambitious 90-90-90 HIV treatment targets set by the Joint United Nations Programme on HIV and AIDS are met. The targets anticipate that by 2020, 90 percent of people living with HIV will be aware of their status, 90 percent of those diagnosed with HIV will begin antiretroviral therapy (ART), and 90 percent of those receiving ART will have long-term viral suppression. Furthermore, the CDC recommends that everyone between 13 and 64 in the United States get tested for HIV at least once.

The drawbacks associated with HIV diagnostics testing is expected to hamper the market growth

The window period is one of the most serious issues with HIV testing (the time between a person being infected with HIV and their body producing enough antibodies for a test to detect). A negative test result could indicate that someone was recently infected with HIV. A positive test result can sometimes be a 'false positive,' leading the person to believe they have HIV when they do not. A negative test result could be a 'false negative,' implying that the person believes they do not have HIV when they do. The cost of testing is also one major reason expected to hamper the market. For instance, HIV testing is extremely expensive. It puts a strain on healthcare budgets in areas where resources are scarce. Except for blood transfusion services, where testing is required, the benefits of testing must be carefully considered. In addition, despite having enough trained counselors, the hospital lacks funds to cover the cost of testing kits, and the supply is unreliable.

COVID-19 Impact Analysis

Over the last year, the occurrence of the COVID-19 pandemic had a significant negative impact on healthcare systems. Healthcare providers were forced to focus primarily on COVID-19 patients, ignoring equally important diseases, both acute and chronic, in many cases. As a result, HIV screening and diagnostic strategies may have been significantly hampered. During the pandemic, there was a significant reduction in HIV diagnoses. People living with HIV during the pandemic, on the other hand, were older and diagnosed at an earlier stage of disease (based on CD4+ T cell count) than those diagnosed the previous year. Furthermore, there was a significant decrease in new HIV diagnoses among men who have sex with men, most likely due to the government's social distancing and restrictions. Even if the number of late presentations in 2020 is lower than in 2019, it remains an issue.

Segment Analysis

By test type, the antibody tests segment is expected to dominate the market

HIV antibodies are detected in blood or saliva by the Antibody test. When bacteria or viruses enter the body, the immune system produces antibodies. After 3–12 weeks of infection, an HIV antibody test can determine if the person is positive. This can take several weeks or longer for the immune system to produce antibodies against HIV. With the kits, the patient can perform an HIV antibody test in the privacy of their own home. The majority of rapid and self-tests are antibody tests. In general, antibody tests using blood from a vein can detect HIV sooner than tests using blood from a finger prick or oral fluid.

Furthermore, on September 30th, 2020, Roche launched the Elecsys HIV Duo immunoassay in the United States. This test can detect an acute HIV infection earlier than current methods by measuring the HIV p24 antigen (the virus) and anti-HIV antibodies.

Geographical Analysis

North America region is expected to hold the largest market share in the global HIV diagnostics testing market

The presence of key players, the high prevalence of HIV/AIDS in the region, and established healthcare infrastructure are some of the key factors expected to drive the market in this region. According to the most recent Centers for Disease Control and Prevention estimates, 37,832 people in the United States were diagnosed with HIV in 2018. Furthermore, advantageous government initiatives and an increase in research collaborations. The CDC in the United States recommends routine HIV screening in healthcare settings for all adults aged 13 to 64, with at least annual repeat screening for those at higher risk.

Competitive Landscape

The global HIV diagnostics testing market is highly competitive with mergers, collaborations, and product launches. Some of the key players in the market are Siemens Healthineers, F. Hoffmann-La Roche Ltd, Abbott Laboratories, Danaher Corporation, Thermo-Fisher Scientific Inc., Merck KGaA, Becton, Dickinson & Company, Hologic Inc., JOYSBIO (Tianjin) Biotechnology Co., Ltd., and Bio-Rad Laboratories

F. Hoffmann-La Roche Ltd

Overview: Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is one of the largest biotech companies, with differentiated medicines in oncology, immunology, infectious diseases, ophthalmology, and neuroscience. Roche is a global leader in in vitro and tissue-based cancer diagnostics and a frontrunner in diabetes management.

Product Portfolio: The Elecsys HIV Duo immunoassay, with two separate measurements, detects both the HIV p24 antigen and anti-HIV antibody. These outcomes are then combined using an algorithm to produce a combined result.

Key Developments: On September 30th, 2020, Roche launched the Elecsys HIV Duo immunoassay in the United States. This test can detect an acute HIV infection earlier than current methods by measuring the HIV p24 antigen (the virus) and anti-HIV antibodies.

Why Purchase the Report?
Visualize the composition of the global HIV diagnostics testing market segmentation by product, by test type, and application highlighting the key commercial assets and players.
Identify commercial opportunities in global HIV diagnostics testing market by analyzing trends and co-development deals.
Excel data sheet with thousands of data points of global HIV diagnostics testing market- level 4/5 segmentation.
PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
Product mapping in excel for the key product of all major market players

The global HIV diagnostics testing market report would provide an access to an approx. 45+market data table, 40+figures and 180 pages.

Target Audience
Service Providers/ Buyers
Industry Investors/Investment Bankers
Education & Research Institutes
Research Professionals
Emerging Companies
Manufacturers

Market Segmentation

Global HIV Diagnostics Testing Market- By Product
Consumables

o Assays and Kits & Reagents

o Other Consumables
Instruments
Software & Services

Global HIV Diagnostics Testing Market- By Test Type
Antibody Tests
Viral Load Tests
CD4 Tests
Other

Global HIV Diagnostics Testing Market- By Application
Diagnostic Laboratories
Hospitals
Other

Global HIV Diagnostics Testing Market- By Region
North America
Europe
South America
Asia Pacific
Middle East and Africa